Erectile dysfunction: An overview

Clinics in Geriatric Medicine

Volumn 19, Issue 3, 2003, Pages 529-538

  Morales, Alvaro ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; APOMORPHINE; HORMONE RECEPTOR STIMULATING AGENT; MELANOTAN; MONOAMINE OXIDASE INHIBITOR; PAPAVERINE; PHENTOLAMINE MESYLATE; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN E1; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TADALAFIL; TESTOSTERONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VARDENAFIL;

AGING; ANORGASMIA; BACKACHE; CANCER; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DEVICE; DIABETES MELLITUS; DYSPEPSIA; EJACULATION DISORDER; EPIDEMIOLOGICAL DATA; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYPOGONADISM; INCIDENCE; LIBIDO DISORDER; MALE SEXUAL DYSFUNCTION; MYALGIA; NAUSEA; PAIN; PATIENT COUNSELING; PENIS PROSTHESIS; PREVALENCE; PROSTATE CANCER; REVIEW; RHINITIS; SIDE EFFECT; VERTIGO; YAWNING;

EID: 0042164940     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0690(02)00104-0     Document Type: Review

References (41)

1. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
2. Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol 2000;163:460-3.
3. Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 2000;12:305-11.
4. Bortz II WM, Wallace DH, Wiley D. Sexual function in 1,202 aging males: differentiating aspects. J Gerontol A Biol Sci Med Sci 1999;54:M237-41.
5. Schiavi RC. Aging and male sexuality. Cambridge: Cambridge University Press; 1999.
6. Greenstein A, Plymate SR, Katz P. Visually stimulated erection in castrated men. J Urol 1995; 153:650-2.
7. Morales A, Johnston B, Heaton JPW, et al. Testosterone supplementation in hypogonadal impotence: assessment of biochemical measurements and therapeutic outcomes. J Urol 1997; 157:849-54.
8. McKinlay JD, Feldman HA. Age related variations in sexual activity and interest in normal men: results of the Massachusetts Male Aging Study. In: Rossi AJ, editor. Sexuality across life course. Chicago: University of Chicago Press; 1994. p. 231-86.
9. Frank E, Anderson C, Rubenstein D. Frequency of sexual dysfunction in "normal" couples. N Engl J Med 1978;299:111-5.
10. Vinik A, Richardson D. Erectile dysfunction in diabetes. Diabetes Rev 1998;6:16-33.
11. Joffres MR, Hamet P, MacLean DR, et al. Distribution of blood pressure and hypertension in Canada and the United States. Am J Hypertens 2001;14:1099-105.
12. Burchardt M, Burchardt T, Baer L, et al. Hypertension is associated with severe erectile dysfunction. J Urol 2000;164:1188-91.
13. Kimura M, Murata Y, Shimoda K, et al. Sexual dysfunction following stroke. Compr Psychiatry 2001;42:217-22.
14. Seidman SN. Exploring the relationship between depression and erectile dysfunction in aging men. J Clin Psychiatry 2002;63:5-12.
15. Kim JE, Moen P. Retirement transitions, gender, and psychological well-being: a life-course, ecological model. J Gerontol B Psychol Sci Soc Sci 2002;57:P212-22.
16. Schiavi RC, Rehman J. Sexuality and aging. Urol Clin North Am 1995;22:711-26.
17. Margolese HC, Assalian P. Sexual side effects of antidepressants: a review. J Sex Marital Ther 1996;22:209-17.
18. Redinbaugh EM, Zeiss AM, Davies HD, et al. Sexual behavior in men with dementing illnesses. Clin Geriatr 1997;5:687-92.
19. Talcott JA, Rieker P, Propert KJ, et al. Patient-reported impotence and incontinence after nervesparing radical prostatectomy. J Natl Cancer Inst 1997;89:1117-23.
20. Mantz CA, Song P, Farhangi E, et al. Potency probability following conformal megavoltage radiotherapy using conventional doses for localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:551-7.
21. Neischlag E, Behere HM. Pharmacological and clinical uses of testosterone. In: Nieschlar A, Behere HM, editors. Testosterone: action, deficiency, substitution. Berlin: Springer-Verlag; 1998. p. 294-321.
22. Burris AS, Banks SM, Carter CS, et al. A long-term prospective study of the physiologic and behavioural effects of hormone replacement in untreated hypogonadal men. J Androl 1992;13:297-304.
23. Sato Y, Shibuya A, Adachi H, et al. Restoration of sexual behavior and dopaminergic neurotransmission by long term exogenous testosterone replacement in aged male rats. J Urol 1998; 160:1572-7.
24. Park KH, Kim SW, Kim KD, et al. Effect of androgen on the expression of nitric oxide synthase (NOS) isoform of mRNAs in the penile corpus cavernosus of castrated rats. BJU Int 1999;83:327-32.
25. Aversa A, Isidori AM, De Martino MU, et al. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol (Oxf) 2000;54:517.
26. Wagner G, Montorsi F, Auerbach S, et al. Sildenafil citrate (Viagra) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. J Gerontol A Biol Sci Med Sci 2001;56:M113-9.
27. Heaton JPW, Morales A, Adams AM, et al. Recovery of erectile function by the oral administration of apomorphine. Urology 1995;45:2000-6.
28. Dula E, Bukofzer S, Perdok R, et al. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 2001;39:558-64.
29. Heaton JPW. Key issues from the clinical trials of apomorphine SL. World J Urol 2001;19:25-31.
30. Finkelstein JS, Kilbanski A, Neer RM, et al. Increases in bone density during treatment of men with idiopathic hypogonadotrophic hypogonadism. J Clin Endocrinol Metab 1989;69:776-83.
31. Negro-Vilar A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab 1999;84:3459-62.
32. Morales A, Lunenfeld B. Androgen replacement therapy in aging men with secondary hypogonadism. Aging Male 2001;4:151-67.
33. Richter S, Vardi Y, Ringel A, et al. Intracavemous injections: still the gold standard for treatment of erectile dysfunction in elderly men. Int J Impot Res 2001;13:172-5.
34. Siddi AA, Becher EF, Zhang G, et al. Patient acceptance and satisfaction with an external negative pressure device for impotence. J Urol 1990;144:1154-6.
35. Steidle CP, Feldman RA, Lettierri J, et al. Pharmacokinetics of vardenafil (a new selective PDE5 inhibitor) in the elderly and subgroup data on efficacy and safety in elderly patients with erectile dysfunction. J Am Geriatr Soc 2001;49(4 suppl):S103.
36. Donatucci C, Karlin G, Goldfischer E, et al. Influence of age on the efficacy and safety of vardenafil, a novel phosphodiesterase-5 inhibitor, for the treatment of erectile dysfunction. J Am Geriatr Soc 2002;50(4 suppl):S107.
37. Goldstein I, Young J, Fischer J, et al. Vardenafil, a new highly selective PDE5 inhibitor, improves erectile function in patients with diabetes mellitus. Diabetes 2001;50(2 suppl):A114.
38. Brock G, Taylor T, Seger M, et al. Efficacy and tolerability of vardenafil in men with erectile dysfunction following radical prostatectomy. Eur Urol 2002;1(1 suppl):152.
39. Padma-Nathan H, Rosen RC, Shabsigh R, et al. Cialis (IC 351) provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction [abstract 923]. J Urol 2002;165:224.
40. Wessels H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol 1999;160:389-93.
41. Molinoff PB, Earle DC, Shadiak AM, et al. A double-blind placebo-controlled study to evaluate the safety, pharmacokinetics, and erectogenic effect of subcutaneously administered PT-141 in healthy males [abstract]. J Urol 2002;167:LB38.